YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지
DOI QR코드

DOI QR Code

ABCB1 Polymorphisms and Imatinib Response in Chronic Myeloid Leukemia Patients: A Systematic Review and Meta-analysis

ABCB1 유전적 다형성이 만성 골수성 백혈병 환자의 Imatinib 치료 반응에 미치는 영향: 체계적 문헌고찰 및 메타분석

  • Received : 2016.04.04
  • Accepted : 2016.04.25
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

A growing number of studies have demonstrated that ABCB1 gene polymorphisms are associated with the variability of responses to imatinib. However, the effects of ABCB1 polymorphisms on imatinib response in chronic myeloid leukemia (CML) are inconsistent. The aim of the present study was to clarify the associations between ABCB1 polymorphisms and imatinib response in CML. A systematic literature review was performed. The databases of PubMed, Embase, and Cochrane Library were searched for all published studies from inception to December 2015. The following terms were used with functions of 'AND' and 'OR': 'chronic myeloid leukemia', 'CML', 'ABCB1', 'MDR1', 'polymorphism', 'SNP', and 'imatinib'. Using the Review Manager 5, odds ratios (ORs) were pooled to estimate the effect of ABCB1 polymorphisms on imatinib response in CML. The pooled analysis showed that ABCB1 2677 G allele was significantly associated with poor response to imatinib in African and Asian patients (GG vs TT, OR: 0.32, p<0.0001; GG+GT vs TT, OR: 0.44, p=0.0005). In subgroup analyses, African patients carrying ABCB1 1236 C allele exhibited higher risk for worse response, whereas Asian patients with 1236 C allele showed better response (CC+CT vs TT, OR: 0.41, p=0.008 for African; OR: 1.65, p=0.03 for Asian). There was no association between C3435T polymorphisms and imatinib response in African, Asian, and Caucasian CML patients.

Keywords

References

  1. Kurzrock, R., Kantarjian, H. M., Druker, B. J. and Talpaz, M. : Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819 (2003). https://doi.org/10.7326/0003-4819-138-10-200305200-00010
  2. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M. A., Iyer, V., Chen, T. T., Huang, F., Decillis, A. P. and Sawyers, C. L. : Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531 (2006). https://doi.org/10.1056/NEJMoa055229
  3. Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Martinelli, G., Mayer, J., Muller, M. C., Niederwieser, D., Pane, F., Radich, J. P., Rousselot, P., Saglio, G., Saubele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J. L., Goldman, J. M. and Hehlmann, R. : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872 (2013). https://doi.org/10.1182/blood-2013-05-501569
  4. Breccia, M., Alimena, G., Baccarani, M., Bocchia, M., Di Raimondo, F., Gambacorti-Passerini, C., Gozzini, A., Morra, E., Pane, F., Pregno, P., Rege-Cambrin, G., Rosti, G., Specchia, G., Vigneri, P. and Saglio, G. : Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. Crit. Rev. Oncol. Hematol. 90, 181 (2014).
  5. National Institute for Health and Care Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. Available from URL: https://www.nice.org.uk/guidance/ta70/chapter/1-guidance. Accessed 25 January (2016).
  6. Bixby, D. and Talpaz, M. : Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am. Soc. Hematol. Educ. Program 461 (2009).
  7. Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E. and Altman, R. B. : Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics 21, 152 (2011). https://doi.org/10.1097/FPC.0b013e3283385a1c
  8. Zu, B., Li, Y., Wang, X., He, D., Huang, Z. and Feng, W. : MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 15, 667 (2014). https://doi.org/10.2217/pgs.13.222
  9. Zheng, Q., Wu, H., Yu, Q., Kim, D. H., Lipton, J. H., Angelini, S., Soverini, S., Vivona, D., Takahashi, N. and Cao, J. : ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 15, 127 (2015). https://doi.org/10.1038/tpj.2014.54
  10. Wang, J. L., Liu, H. J., Li, F., Yang, W. Y., Wang, J. M., Tan, S. F. and Wang, Q. : Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia. Genet. Mol. Res. 14, 14967 (2015). https://doi.org/10.4238/2015.November.24.4
  11. Wells, G. A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M. and Tugwell, P. : The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Ottawa Hospital Research Institute. Available from URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 20 January (2016).
  12. Zheng, J. S., Hu, X. J., Zhao, Y. M., Yang, J. and Li, D. : Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 346, f3706 (2013). https://doi.org/10.1136/bmj.f3706
  13. Xuan, C., Zhang, B. B., Li, M., Deng, K. F., Yang, T. and Zhang, X. E. : No association between APOE ${\varepsilon}$ 4 allele and multiple sclerosis susceptibility: a meta-analysis from 5472 cases and 4727 controls. J. Neurol. Sci. 308, 110 (2011). https://doi.org/10.1016/j.jns.2011.05.040
  14. Zhang, B. B., Xuan, C., Deng, K. F., Wu, N. and Lun, L. M. : Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. Eur. J. Cancer Care (Engl). 22, 617 (2013). https://doi.org/10.1111/ecc.12067
  15. Ali, M. A. and Elsalakawy, W. A. : ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Med. Oncol. 31, 279 (2014). https://doi.org/10.1007/s12032-014-0279-y
  16. Elghannam, D. M., Ibrahim, L., Ebrahim, M. A., Azmy, E. and Hakem, H. : Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology 19, 123 (2014). https://doi.org/10.1179/1607845413Y.0000000102
  17. Maffioli, M., Camos, M., Gaya, A., Hernandez-Boluda, J. C., Alvarez-Larran, A., Domingo, A., Granell, M., Guillem, V., Vallansot, R., Costa, D., Bellosillo, B., Colomer, D. and Cervantes, F. : Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk. Res. 35, 1014 (2011). https://doi.org/10.1016/j.leukres.2010.12.004
  18. Vivona, D., Bueno, C. T., Lima, L. T., Hirata, R. D., Hirata, M. H., Luchessi, A. D., Zanichelli, M. A., Chiattone, C. S. and Guerra-Shinohara, E. M. : ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol. Dis. 48, 132 (2012). https://doi.org/10.1016/j.bcmd.2011.11.001
  19. Gromicho, M., Magalhaes, M., Torres, F., Dinis, J., Fernandes, A. R., Rendeiro, P., Tavares, P., Laires, A., Rueff, J. and Sebastiao Rodrigues, A. : Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol. Rep. 29, 741 (2013). https://doi.org/10.3892/or.2012.2153
  20. Seong, S. J., Lim, M., Sohn, S. K., Moon, J. H., Oh, S. J., Kim, B. S., Ryoo, H. M., Chung, J. S., Joo, Y. D., Bang, S. M., Jung, C. W., Kim, D. H., Park, S. Y., Yoon, S. S., Kim, I., Lee, H. G., Won, J. H., Min, Y. H., Cheong, J. W., Park, J. S., Eom, K. S., Hyun, M. S., Kim, M. K., Kim, H., Park, M. R., Park, J., Kim, C. S., Kim, H. J., Kim, Y. K., Park, E. K., Zang, D. Y., Jo, D. Y., Lee, H. W. and Yoon, Y. R. : Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann. Oncol. 24, 756 (2013). https://doi.org/10.1093/annonc/mds532
  21. Au, A., Aziz Baba, A., Goh, A. S., Wahid Fadilah, S. A., The, A., Rosline, H. and Ankathil, R. : Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed. Pharmacother. 68, 343 (2014). https://doi.org/10.1016/j.biopha.2014.01.009
  22. Salimizand, H., Amini, S., Abdi, M., Ghaderi, B. and Azadi, N. A. : Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour. Biol. DOI 10.1007/s13277-015-3874-4 (2015).
  23. Takahashi, N., Miura, M., Scott, S. A., Kagaya, H., Kameoka, Y., Tagawa, H., Saitoh, H., Fujishima, N., Yoshioka, T., Hirokawa, M. and Sawada, K. : Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet. 55, 731 (2010). https://doi.org/10.1038/jhg.2010.98
  24. Ni, L. N., Li, J. Y., Miao, K. R., Qiao, C., Zhang, S. J., Qiu, H. R. and Qian, S. X. : Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol. 28, 265 (2011). https://doi.org/10.1007/s12032-010-9456-9
  25. Anthony, A., Ankathil, R., Ai-Sim, G., Fadilah, S. A. W. and Baba, A. A. : Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylate in chronic myeloid leukemia patients. IJESD 3, 274 (2012).
  26. Shinohara, Y., Takahashi, N., Nishiwaki, K., Hino, M., Kashimura, M., Wakita, H., Hatano, Y., Hirasawa, A., Nakagawa, Y., Itoh, K., Masuoka, H., Aotsuka, N., Matsuura, Y., Takahara, S., Sano, K., Kuroki, J., Hata, T., Nakamae, H., Mugitani, A., Nakane, T., Miyazaki, Y., Niioka, T., Miura, M. and Sawada, K. : A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 98, 1407 (2013). https://doi.org/10.3324/haematol.2013.085167
  27. Kassogue, Y., Dehbi, H., Quachouh, M., Quessar, A., Benchekroun, S. and Nadifi, S. : Lack of association of multidrug resistance gene-1 polymorphisms with treatment outcome in chronic myeloid leukemia patients treated with imatinib. MEJC 6, 229 (2015).
  28. Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J., Molimard, M., Krajinovic, M. and Mahon, F. X. : Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112, 2024 (2008). https://doi.org/10.1182/blood-2008-03-147744
  29. Sailaja, K., Surekha, D., Rao, D. N., Raghunadharao, D. and Vishnupriya, S. : Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia. Biology and Medicine 2, 17 (2010).
  30. Griffin, J. D., Guerin, A., Chen, L., Macalalad, A. R., Luo, J., Ionescu-Ittu, R. and Wu, E. Q. : Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib--a retrospective chart review analysis. Curr. Med. Res. Opin. 29, 623 (2013). https://doi.org/10.1185/03007995.2013.789012
  31. Kim, D. H., Kong, J. H., Byeun, J. Y., Jung, C. W., Xu, W., Liu, X., Kamel-Reid, S., Kim, Y. K., Kim, H. J. and Lipton, J. H. : The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 16, 5339 (2010). https://doi.org/10.1158/1078-0432.CCR-10-1638
  32. Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., Paliompeis, C., Latham, V., Foroni, L., Molimard, M., Reid, A., Rezvani, K., de Lavallade, H., Guallar, C., Goldman, J. and Khorashad, J. S. : Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28, 2381 (2010). https://doi.org/10.1200/JCO.2009.26.3087
  33. Deenik, W., van der Holt, B., Janssen, J. J., Chu, I. W., Valk, P. J., Ossenkoppele, G. J., van der Heiden, I. P., Sonneveld, P., van Schaik, R. H. and Cornelissen, J. J. : Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood 116, 6144; author reply 6145 (2010). https://doi.org/10.1182/blood-2010-07-296954
  34. Dulucq, S., Preudhomme, C., Guilhot, F. and Mahon, F.-X. : Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood 116, 6145 (2010). https://doi.org/10.1182/blood-2010-08-298794